clinical research and accordingly develop a strategic plan to this effect. (4, 5) In order to be able to institute such a plan, it is essential that the various opportunities and challenges be recognised.
global knowledge about locally, as well as generally, prevalent diseases in terms of prevention and treatment". (2) Although there have been a number of initiatives designed to strengthen research capacity in Africa over the past few years, the success thereof is difficult to measure. The Thomson Reuters Global research report attempts to do so by reporting the volume of scientific publications produced by various countries over the continent. Not surprisingly, the six leading African countries by output (namely South Africa, Egypt, Nigeria, Tunisia, Algeria and Kenya) also correspond with four of the leading countries in terms of gross domestic product (GDP). However, it is clear that the continent's research output is still small and needs to be further addressed. increasing number of orphans in the care of the poor and weak elderly populations. (7) A great amount of original research is needed in cardiac disorders that are either common or rare in the black African population. Implementing preventative strategies for these conditions depend on social changes, improving primary healthcare services, elimination of poverty, better housing and an enhanced knowledge of the disease process through research and development programmes that are currently constrained by staffing and budgetary restrictions. (6) Studies in the 1970s to 1980s suggested that the prevalence of cardiovascular disease(CVD) was low in the black African population. (8) However, CVD has since become an ever-present cause of morbidity and a leading cause of mortality in South Africa,
Zimbabwe and the rest of sub-Saharan Africa, partly due to the presence of determinants and risk factors in these societies. (9, 10) In fact, CVD is the second highest cause of death in most African and low-income countries, accounting for 10% of all deaths. (11) It is estimated that this burden will double from 1990 to 2020. (11) The effects of CVD are well documented in developed countries.
However, reliable data describing the burden of this epidemic in developing countries associated with a high prevalence of malnourishment and infectious diseases is scant. Currently, developing countries contribute a greater share to the global burden of CVD than developed countries; it has been estimated that 5.3 million deaths were attributed to CVD in developed countries in 1990 compared to 8 to 9 million deaths in developing countries. (12) In South Africa, CVD, diabetes, respiratory disease and cancer have been heralded as the "silent killers" of this socially and culturally diverse population. One in three men and 50% of all women are overweight. (13) Increasing urbanisation and resultant unhealthy lifestyles, lead to the appearance of various chronic diseases of lifestyle risk factors such as hyperlipidaemia, diabetes, atherosclerosis, obesity, hypertension and an increasing tobacco addiction.
Amongst these, CVD is the most common cause of death for people age 45 and older. (13) The public health system, already under pressure to manage the 
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and talents are better rewarded and better appreciated. (1) According to ASSAf, the clinical research force is ageing and has been steadily declining in numbers since the early 1990s. (2) In this age of evidence-based medicine, clinical guidelines and health policies should ideally be based on well-run, local, randomised controlled trials.
African governments need to provide the basic infrastructure for health research. While these various initiatives and schemes are headed in the right direction, they may fail to achieve their aims because of no coordination and duplication of effort.
(1) The EDCTP, for instance, certainly did not get off to an auspicious start with the ousting of its executive director at the first annual forum and rumblings of discontent among grant applicants with regards to poor administration. (18) Lessons from other sectors such as agriculture and education also need to be sought and discussed.
lack of funding foR clinical ReseaRch
In 2007, the African Union members pledged to spend 1% of their GDP on research and development. (19) According to ASSAf, 2% of GDP is the necessary minimum investment in indigenous science and technology development, with health research receiving at least 20% of this amount. (2) Currently in South Africa, 10.8% of all government expenditure is on health and, according to the National Health Expenditure Review in 1991/1992, it was estimated that about 1.1% of this was spent on research. South Africa is spending more on research and development than before, but it is still considerable less than 1% of GDP.
Clinical researchers are thus being left with no alternative but to rely on funding from the pharmaceutical industry (whose predominant interest is aimed at profitable areas such as chronic diseases of lifestyle, mental illness and allergies) and international donors (whose predominant interest is HIV and tuberculosis). (16) The overall effect of this is that the local needs of the countries are being bypassed. Governments from these nations accordingly need to start recognising that research funds are a "good investment". 
language baRRieR
Africa, with its rich cultural heritage, diverse population and wealth of traditional knowledge has a lot to offer modern science, but much is lost due to language constraints. Conversely, this also poses a problem when science cannot be translated into local languages.
In South Africa, for instance, there are 11 official languages and a population consisting of black Africans 79%, white 9.6%, coloured 8.9% and Asian 2.5%. (13) Translations are usually required for the informed consent forms and patient information brochures, however English is acceptable for the clinical protocols, CRFs and Investigators Brochures.
The translation of African languages and practices results in a great deal of local knowledge being lost, and leads to farmers and rural communities being excluded from the modernisation of science and technology, as there are no local terminology or expressions to explain or translate the two concepts. (19) Zimbabwean scientists are currently compiling a Shona dictionary, a language currently being spoken by 9 million Zimbabweans. (19) One of the problems with this dictionary is the inability of literal translations to adequately explain an entire concept. Furthermore, translations can only succeed when sufficient funding is available.
infoRmed consent
In African communities, important concepts of informed consent such as risk-benefit ratio, fair treatment of participants and voluntary participation, are interpreted in a different way. (29) However, the recruitment of participants in clinical trials remains essential to the success of the trial. In third world countries, participant recruitment is complicated by political, ethical, social and scientific concerns, especially when research is funded by affluent countries. (29) According to the Declaration of Helsinki, when undertaking "medical research on human subjects, considerations related to the wellbeing of the human subject should take precedence over the interests of science and society". (30) The process of individual informed consent of subjects is, accordingly, crucial. Furthermore, the possibility of misinterpretation of the consent form poses a real threat, and it may result in no permission being granted to enter the study.
Informed consent forms (ICF) often present highly complex information that needs to be understood by patients. It is important that subjects truly understand specific elements in the ICF, including the purpose of the study, the randomisation process, and risks and benefits in participating, and that participation is voluntary.
Complexity of the consent form has been shown to be a major barrier to comprehension for many patients. Examples of these (32) It is the investigator's responsibility to ensure that a potential trial subject is competent to fully understand the informed consent.
A study conducted in a cardiology research unit in Cape Town, South Africa demonstrated that, despite adequate time and explanations being provided by researchers, participant understanding of certain research terminologies, such as randomisation and placebo, were poor. (33) Thus more time and effort are needed for participants with lower levels of education and/or little experience of research or medical contexts. A person is deemed competent if "able to understand a therapy or research procedure, to deliberate major risks and benefits, and to make a decision in light of this deliberation". (29) Due to malnourishment and poverty, people in developing countries do not have equal opportunities for education and are commonly considered illiterate or uneducated. These people are classified as vulnerable research subjects because they often lack the capacity or competency to give informed consent. People in vulnerable communities often do not understand the complicated protocol requirements or procedures, which results in them being unable to decide whether or not to participate in a trial.
oppoRtunities and conceRns RegaRding globalisation of clinical ReseaRch
In recent years, there has been a significant geographical shift in the conduct of clinical research from first world countries, such as Register (SANCTR), with cardiovascular diseases and diabetes mellitus accounting for just over 10%. (35) Key factors for the growth in clinical trials in South Africa include a history of high quality medical research, a high burden of disease and relatively drug-naïve populations. (36) There are a number of concerns associated with this policy of globalisation, including:
■ Lengthy regulatory approval times.
■ Concern over the standard of data.
■ Lack of confidentiality.
■ Dodgy recruitment methods.
■ Inexperienced and inadequate ethics committees. (37) There have also been numerous instances where pharmaceutical companies have attempted to pursue clinical trials in developing countries which would not be considered ethical or practical in a developing country. (38) A good example of this is the Trovan meningitis study in Nigeria during 1996. (23) Emanuel has identified three controversial issues with regards to the conduct of clinical trials in developing countries that need to be addressed, namely the standard of care to which investigational treatments should be compared, the "reasonable availability" of proven interventions demonstrated to be beneficial during the study, and the "quality of the informed consent" process. sites. (38) These can impact heavily on the conduct of the trial and hence the integrity of the data. In some cases, safety of site personnel can also be problematic.
■ Ethical and regulatory concerns, as discussed above.
■ Population diversity: The increasing environmental, cultural and ethnic diversity of the research participants may pose problems in reaching conclusions -for example, angioneurotic oedema secondary to ACE-inhibitors is more common in African Americans than in white patients. (22, 38) In addition, it is important that sponsors obtain the commitment, support and understanding of local leaders, health workers and their customs. (38) Care must be taken to ensure that the project is not perceived as "exploitative". (38, 39) ■ Suitability of clinical research to the population: There are ethical concerns about researching drugs in a community in which the sponsor has no intention of marketing the drug.
Medication that is affordable in first world countries is often too expensive for the majority of patients in developing countries; relevant strategies need to be researched for these countries. (38, 40) In addition, historically, uneducated, socioeconomically-deprived populations were "targeted for high-risk research, whereas promising research was offered in more privileged individuals. (39) ■ The potential vulnerability of the population group must be recognised and not exploited. In some instances, remuneration for study participation may be excessive. (40, 41) In addition, trial participation may be the only way in which patients can gain access to medical services and medication to which they would otherwise be denied. This finding was confirmed in a South African study where more than 90% of respondents listed this as a reason for volunteering for a clinical trial. (42) ■ Other local issues, such as the use of over-the-counter concomitant medications, particularly local herbal remedies, which can cause unexpected drug interactions and adverse effects. (38) Other issues raised by Glickman include: "transparency of clinical trial results" and subsequent "protection of publication rights and access to trial data", and "genomic information in drug development". (40) Despite these challenges, there are a number of signs that developing countries are meeting the desired quality of performance.
Yusuf has analysed the performance of developing countries in a number of international randomised control levels and demonstrated that the quality of data, patient attrition and overall study performance was on par with first world countries. (38) In South Africa, for instance, a total of 37 sites were audited by the Food and Drug Administration (FDA) of America from 1994 to 2009. (43) The most common deficiencies were "failure to follow the investigational plan" (15 sites) and "inadequate and inaccurate records" (8 sites). There was a single inspection in 1997 that resulted in an "Official Action Indicated" report being generated, with the deficiency being cited as "inadequate and inaccurate records". These findings are shown in Table I , and are better than many FDA inspection findings from developed countries. In addition, initiatives aimed at improving the education of the whole population regarding Western medicine must be stepped up in order to allay fears among some ethnic groups that Western medicine may be harmful and to provide reassurance that the aim of these trials is to promote the health of everyone, including the people of Africa. 
